Your browser doesn't support javascript.
loading
A retrospective analysis of mature T- and NK-cell lymphomas.
Jia, Junlei; Wang, Xiaohui; Song, Zheng; Meng, Shen; Fei, Yue; Yu, Jingwei; Liu, Xia; Han, Xue; Li, Lanfang; Qiu, Lihua; Qian, Zhengzi; Zhou, Shiyong; Gong, Wenchen; Meng, Bin; Ren, Xiubao; Wang, Xianhuo; Zhang, Huilai.
Affiliation
  • Jia J; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Wang X; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Song Z; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Meng S; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Fei Y; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
  • Yu J; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Liu X; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Han X; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Li L; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Qiu L; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Qian Z; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Zhou S; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Gong W; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
  • Meng B; Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China.
  • Ren X; Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China.
  • Wang X; Department of Immunology/Biotherapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China.
  • Zhang H; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, and Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prev
Cancer Biol Med ; 21(3)2024 Mar 27.
Article in En | MEDLINE | ID: mdl-38544483
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Killer Cells, Natural / Lymphoma Limits: Humans Language: En Journal: Cancer Biol Med Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Killer Cells, Natural / Lymphoma Limits: Humans Language: En Journal: Cancer Biol Med Year: 2024 Document type: Article